TriSalus Life Sciences (TLSI) Stock Forecast, Price Target & Predictions
TLSI Stock Forecast
TriSalus Life Sciences stock forecast is as follows: an average price target of $11.00 (represents a 144.44% upside from TLSI’s last price of $4.50) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
TLSI Price Target
The average price target for TriSalus Life Sciences (TLSI) is $11.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $10.00. This represents a potential 144.44% upside from TLSI's last price of $4.50.
TLSI Analyst Ratings
According to 2 Wall Street analysts, TriSalus Life Sciences's rating consensus is 'Buy'. The analyst rating breakdown for TLSI stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
TriSalus Life Sciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 16, 2024 | Suraj Kalia | Oppenheimer | $10.00 | $4.52 | 121.24% | 122.22% |
| Jul 02, 2024 | William Plovanic | Canaccord Genuity | $12.00 | $5.33 | 125.14% | 166.67% |
The latest TriSalus Life Sciences stock forecast, released on Sep 16, 2024 by Suraj Kalia from Oppenheimer, set a price target of $10.00, which represents a 121.24% increase from the stock price at the time of the forecast ($4.52), and a 122.22% increase from TLSI last price ($4.50).
TriSalus Life Sciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 2 |
| Avg Price Target | - | $10.00 | $11.00 |
| Last Closing Price | $4.50 | $4.50 | $4.50 |
| Upside/Downside | -100.00% | 122.22% | 144.44% |
In the current month, the average price target of TriSalus Life Sciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to TriSalus Life Sciences's last price of $4.50. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 16, 2024 | Oppenheimer | - | Outperform | Initialise |
| Jul 02, 2024 | Canaccord Genuity | Buy | Buy | Hold |
TriSalus Life Sciences's last stock rating was published by Oppenheimer on Sep 16, 2024. The company Initialise its TLSI rating from "null" to "Outperform".
TriSalus Life Sciences Financial Forecast
TriSalus Life Sciences Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $18.27M | $17.59M | $16.24M | $15.56M | $12.39M | $10.97M | $10.53M | $9.49M | $8.18M | $7.38M | $6.88M | $6.17M | $5.45M |
| High Forecast | $18.27M | $17.59M | $16.24M | $15.56M | $12.39M | $10.97M | $10.53M | $9.49M | $8.18M | $7.57M | $6.88M | $6.17M | $5.45M |
| Low Forecast | $18.27M | $17.59M | $16.24M | $15.56M | $12.39M | $10.97M | $10.53M | $9.49M | $8.18M | $7.18M | $6.88M | $6.17M | $5.45M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
TriSalus Life Sciences's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. TLSI's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
TriSalus Life Sciences EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-18.27M | $-17.59M | $-16.24M | $-15.56M | $-12.39M | $-10.97M | $-10.53M | $-9.49M | $-8.18M | $-7.38M | $-6.88M | $-6.17M | $-5.45M |
| High Forecast | $-18.27M | $-17.59M | $-16.24M | $-15.56M | $-12.39M | $-10.97M | $-10.53M | $-9.49M | $-8.18M | $-7.18M | $-6.88M | $-6.17M | $-5.45M |
| Low Forecast | $-18.27M | $-17.59M | $-16.24M | $-15.56M | $-12.39M | $-10.97M | $-10.53M | $-9.49M | $-8.18M | $-7.57M | $-6.88M | $-6.17M | $-5.45M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict TLSI's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than TriSalus Life Sciences's previous annual EBITDA (undefined) of $NaN.
TriSalus Life Sciences Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | $-6.04M | $-6.39M | $-6.62M | $-6.47M | $-7.53M | $-8.29M | $-10.98M | $-13.86M | $-16.49M |
| High Forecast | - | - | - | - | $-6.04M | $-6.39M | $-6.62M | $-6.47M | $-7.53M | $-8.06M | $-10.98M | $-13.86M | $-16.49M |
| Low Forecast | - | - | - | - | $-6.04M | $-6.39M | $-6.62M | $-6.47M | $-7.53M | $-8.29M | $-10.98M | $-13.86M | $-16.49M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
TriSalus Life Sciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TLSI's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
TriSalus Life Sciences SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $39.51M | $38.05M | $35.12M | $33.66M | $26.81M | $23.73M | $22.78M | $20.54M | $17.69M | $15.96M | $14.88M | $13.34M | $11.80M |
| High Forecast | $39.51M | $38.05M | $35.12M | $33.66M | $26.81M | $23.73M | $22.78M | $20.54M | $17.69M | $16.38M | $14.88M | $13.34M | $11.80M |
| Low Forecast | $39.51M | $38.05M | $35.12M | $33.66M | $26.81M | $23.73M | $22.78M | $20.54M | $17.69M | $15.54M | $14.88M | $13.34M | $11.80M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
TriSalus Life Sciences's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to TLSI last annual SG&A of $NaN (undefined).
TriSalus Life Sciences EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | $-0.25 | $-0.27 | $-0.28 | $-0.27 | $-0.32 | $-0.35 | $-0.46 | $-0.58 | $-0.69 |
| High Forecast | - | - | - | - | $-0.25 | $-0.27 | $-0.28 | $-0.27 | $-0.32 | $-0.34 | $-0.46 | $-0.58 | $-0.69 |
| Low Forecast | - | - | - | - | $-0.25 | $-0.27 | $-0.28 | $-0.27 | $-0.32 | $-0.35 | $-0.46 | $-0.58 | $-0.69 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, TriSalus Life Sciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TLSI previous annual EPS of $NaN (undefined).